Giuseppe Derosa^{1, 2,}, Angela D’Angelo^{1, 3}, Pamela Maffioli^{1, 4}

The primary endpoint of the current study was to evaluate whether the effects previously demonstrated in the 3-month study could be maintained for 12 months. Patients were randomized to take Glicoset® in addition to a standardized diet, or to follow a standardized diet alone for 12 months. Glicoset® was self-administered once a day, 1 tablet during the breakfast. After 12 months, 31.9 % of patients retuned to a normal glycemic status in the group treated with nutraceutical + diet vs 3.3 % of patients in diet alone group (p < 0.05). At the end of the study 43.6% were classified as IFG in the group treated with nutraceutical + diet group vs 37% in diet alone group (p < 0.05). In the group treated with nutraceutical + diet, 24.5% were classified as IGT at the end of the study vs 51.1% in diet alone group (p < 0.01). In diet alone group, 8.7% developed type 2 diabetes mellitus vs 0 patients in diet + nutraceutical group (p < 0.05). Total cholesterol, LDL-C, and Tg were lower in the group treated with the nutraceutical combination. The positive effects on glycemic and lipid profile already showed in a 3 months study were also maintained after 12 months of treatment with a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate.

Ilex Paraguariensis, White Mulberry, Chromium Picolinate